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University of Gdańsk, Poland
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Better understanding of roles of complement in pathology has fuelled an explosion of
interest in complement-targeted therapeutics. The C5-blocking monoclonal antibody
(mAb) eculizumab, the first of the new wave of complement blocking drugs, was FDA
approved for treatment of Paroxysmal Nocturnal Hemoglobinuria in 2007; its expansion
into other diseases has been slow and remains restricted to rare and ultra-rare diseases
such as atypical hemolytic uremic syndrome. The success of eculizumab has provoked
other Pharma to follow this well-trodden track and made C5 blockade the busiest area of
complement drug development. C5 blockade inhibits generation of C5a and C5b, the
former an anaphylatoxin, the latter the nidus for formation of the pro-inflammatory
membrane attack complex. In order to use anti-complement drugs in common
complement-driven diseases, more affordable and equally effective therapeutics are
needed. To address this, we explored complement inhibition downstream of C5. Novel
blocking mAbs targeting C7 and/or the C5b-7 complex were generated, identified using
high throughput functional assays and specificity confirmed by immunochemical assays
and surface plasmon resonance (SPR). Selected mAbs were tested in rodents to
characterize pharmacokinetics, and therapeutic capacity. Administration of a mouse
C7-selective mAb to wildtype mice, or a human C7 specific mAb to C7-deficient mice
reconstituted with human C7, completely inhibited serum lytic activity for >48 h. The C5b-
7 complex selective mAb 2H2, most active in rat serum, efficiently inhibited serum lytic
activity in vivo for over a week from a single low dose (10 mg/kg); this mAb effectively
blocked disease and protected muscle endplates from destruction in a rat myasthenia
model. Targeting C7 and C7-containing terminal pathway intermediates is an innovative
therapeutic approach, allowing lower drug dose and lower product cost, that will facilitate
the expansion of complement therapeutics to common diseases.
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The complement system comprises over 50 proteins, regulators
and receptors circulating in plasma or on cells. Activation of the
system by three distinct pathways, classical, lectin, and
alternative, the latter comprising a common amplification loop,
leads to formation of C3 convertases, followed by C5 convertases
which cleave C5 into the potent chemotactic anaphylatoxin C5a,
and C5b, the nidus for formation of the cytotoxic proinflammatory
membrane attack complex (MAC). C5b while associated with the
convertase, sequentially binds the plasma proteins C6 and C7,
generating the C5b-7 complex that undergoes conformational
change, triggering release from the convertase and exposing a
labile hydrophobic membrane binding surface. The C5b-7
complex through its hydrophobic surface tightly binds membrane
and sequentially recruits C8 and C9 to create the MAC, a
transmembrane pore comprising one molecule each of C5b, C6,
C7, and C8 and up to 18 copies of C9 that are recruited sequentially.
The MAC pore allows metabolites and small proteins to leak out of
the cell and water to flood into the cell due to osmotic pressure
leading to lytic cell death (1–3).
Complement is critical to immune defense, providing
recognition, tagging and elimination of bacteria and other
foreign intruders and immune complexes; however,
inappropriate activation of the system can lead to self-tissue
and self-cell damage, driving disease. Hence, there is a need for
therapies that block complement. For more than a decade, there
was only one anti-complement drug in the clinic, the anti-C5
monoclonal antibody (mAb) eculizumab; this drug was FDA
approved in 2007 for the ultra-rare hemolytic disease paroxysmal
nocturnal hemoglobinuria (PNH), in 2011 for the ultra-rare
renal disease atypical hemolytic uremic syndrome (aHUS), and
for myasthenia gravis (MG) therapy in 2017 and in 2019 for the
treatment of anti-aquaporin-4 (AQP4) antibody positive
neuromyelitis optica spectrum disorder (NMOSD) in adults
(1). At a list price of approximately $500,000 per patient per
year, eculizumab, remains one of the most expensive therapies in
the world. The drug must be given bi-weekly by intravenous
infusion, 0.9 to 1.2 g/dose (1–5). These factors restrict progress
toward therapy of more common complement-driven diseases. A
step change is now needed to enable the use of anti-complement
drugs in these conditions where there is considerable unmet need
and many patients do not respond adequately to currently
available agents. Anti-complement drugs for common
conditions must be safer, cheaper and easier to administer.
Although the complement cascade can be targeted at many
stages, anti-complement drugs in development are focused on
very few targets, with agents mimicking eculizumab and
targeting C5 or its breakdown products predominating. This is
at least in part because inhibition of C5 has proven to be
relatively low risk; the increased risk of Neisserial infections is
managed by vaccination before treatment and prophylactic use
of antibiotics. There are numerous agents in development that
target C5, for example, crovalimab (SKY59), a C5 blocking mAb
utilizing a pH-dependent recycling technology to increase drug
half-life, and reduce the dose required to block C5 (in phase III
clinical trials; (1, 6) https://clinicaltrials.gov/ct2/show/Frontiers in Immunology | www.frontiersin.org 2NCT04432584), and ravulizumab, the “next generation”
eculizumab that also incorporates recycling technology
enabling an increase in dosing interval to eight weeks.
Ravulizumab has been FDA approved for PNH (2018) and
aHUS (2019) (7).
Currently, only one drug targeting MAC downstream of C5 has
progressed to clinical trials; AAVCAGsCD59 is a gene therapy
agent in development for age-related macular degeneration (AMD);
the agent is injected into the eye to locally express a non-anchored
form of the MAC inhibitor CD59 (8). An anti-C6 mAb (CP010),
developed by Complement Pharma and now partnered with
Alexion, is in pre-clinical testing. (https://globalgenes.org/2018/06/
12/alexion-and-complement-pharma-form-partnership-to-co-
develop-complement-inhibitor-for-neurodegenerative-disorders/).
In the wider literature there are a few preclinical reports describing
targeting MAC beyond C5. An anti-C8 mAb was tested in
hyperacute rejection (HAR) and cardiopulmonary bypass (CPB)
rodent models; (9, 10) in HAR, mAb treatment protected hearts
perfused with human serumwhile in CPB the mAb reduced platelet
activation. A polyclonal antibody against C6 inhibited clinical
symptoms in an experimental MG (EAMG) model in rats (11).
Neither of these agents was advanced further. A very recent report
described a monoclonal anti-C6 that inhibited hemolysis in human
and rhesus monkey serum (12). These reports not only highlight the
therapeutic potential of developing anti-terminal pathway drugs
beyond C5, but also demonstrate the crucial role of MAC as a
pathology driver.
Here we describe a panel of terminal pathway blocking mAbs,
generated in C7-knockout (KO) mice hyper-immunized with
human or rat C5b-7 and/or C7. The selected anti-human mAbs
were equivalent or better inhibitors of human complement when
compared to eculizumab in standard activity assays. Some of the
mAbs showed cross-species activity when tested against human
and rodent sera and the relevant mAbs efficiently inhibited
complement activity in vivo in rodents. For one mAb, reactive
against rat C5b-7, a single low dose inhibited complement for
over a week in rats and blocked disease in the rat EAMG model.MATERIALS AND METHODS
Reagents and Sera
All chemicals, except where otherwise stated, were obtained from
either Fisher Scientific UK (Loughborough, UK) or Sigma
Aldrich (Gillingham, UK) and were of analytical grade. All
tissue culture reagents and plastics were from Invitrogen Life
Technologies (Paisley, UK). Sheep and guinea pig erythrocytes in
Alsever’s solution were from TCS Biosciences (Claydon, UK).
Eculizumab was kindly donated by Prof. David Kanavagh
(Newcastle University, UK), and crovalimab by Roche Diagnostics
(Basel, Switzerland). Cynomolgus monkey serum was purchased
from Serlab (#S-118-D-24526, London, UK). Human and animal
sera were prepared in house from freshly collected blood. For
human, rabbit and rat, blood was clotted at room temperature
(RT) for 1 h, then placed on ice for 2 h for clot retraction before
centrifugation and harvesting of serum. For mouse, blood was
placed on ice immediately after harvest and clotted for 2 h on iceDecember 2020 | Volume 11 | Article 612402
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subjected to freeze–thaw cycles.
Generation of mAbs
Monoclonal antibodies against C7/C5b-7 protein were generated
by first establishing a line of C7 deficient mice. CRISP-generated
heterozygous C7 KO mice (C57BL/6NJ-C7em1(IMPC)J/Mmjax)
were purchased from Jackson Laboratories (Bar Harbour,
Maine, USA) and back-crossed to obtain homozygous C7
deficient mice. The absence of C7 was confirmed by western
blotting (WB) and hemolytic assays (data not shown). Wildtype
(WT) and C7 KO mice were immunized with rat C7 and human
C7/C5b-7 (both purified in-house) using standard schedules
(13). The C7 KO mice were also used as a source of feeder
macrophages during the cloning process. Immunized mice were
screened using enzyme-linked immunosorbent assay (ELISA),
mice with the highest titer response against the immunized
proteins were selected and re-boosted before killing and
harvesting of spleens. Plasma cells were harvested, fused with
SP2 myeloma and aliquoted into 96-well plates. Hybridoma
supernatants were screened using high-throughput hemolytic
assay (described below) to identify blocking mAbs; supernatants
with blocking activity were also screened for antibody responses
by ELISA. Complement blocking mAb-secreting clones were
sub-cloned by limiting dilution to monoclonality. Mouse mAbs
were isotyped using IsoStrips (# 11493027001; Roche).
Hemolytic Assays
The capacity of the mAbs to inhibit complement in human and
animal sera was investigated by classical pathway (CP; CH50)
hemolysis assay using antibody-sensitized sheep erythrocytes
(ShEA); sheep blood was from TCS Bioscience and anti-ShE
antiserum (#ORLC25, Siemens Amboceptor) was from Cruinn
Diagnostics (Dublin, UK). ShEA were suspended in HEPES-
buffered saline (HBS) containing Ca2+ and Mg2+ at 2% (vol:vol)
(14). For measurement of activity in male mouse serum, ShEA
were additionally incubated with mouse anti-rabbit IgG at 25 µg/
ml (#3123; Invitrogen) for 30 min at 37°C before washing in
HBS. A serial dilution series of each test mAb (100–0 µg/ml; 50
µl/well) was prepared in HBS and aliquoted in triplicate into a
96-well round-bottomed plate at 50 µl/well, then serum and 2%
ShEA (50 µl/well of each) added. Serum dilutions for each species
were selected in preliminary experiments to give near complete
hemolysis in the absence of test mAb: 2.5%: normal human
serum (NHS); 10%: normal Cynomolgus monkey serum (Cyno);
2.5% normal rat serum (NRS); 25%: normal rabbit serum
(NRbS); 25%: normal male mouse serum (NMS) (using the
double-sensitized cells as described above). Plates were
incubated at 37°C for 30 min, centrifuged and hemoglobin in
the supernatant was measured by absorbance at 405 nm.
Percentage lysis was calculated according to: % Lysis =
Absorbance (Abs) sample − Abs background)/(Abs max − Abs
background) × 100%. GraphPad Prism was used for data
analysis. Hybridoma supernatants were screened for blocking
mAbs using the same assay but with neat tissue culture
supernatant in place of the purified mAb.Frontiers in Immunology | www.frontiersin.org 3Reactive lysis assays were used to identify mechanism of mAb
inhibition. Guinea pig blood was from TCS; erythrocytes (GPE)
at 2% in HBS (50 µl/well) were incubated sequentially with C5b6,
C7, C8 and C9 (in house, affinity purified (15)), each for 10 min
at 37°C, at doses titrated to give ~75% to 90% hemolysis in the
absence of inhibitor. The concentrations (per well) of the purified
components used were as follow; C5b6; 45 ng/ml, C7; 184 ng/ml,
C8; 168 ng/ml, C9; 383 ng/ml. Molarities in nM; C5b6, 0.16; C7,
1.99; C8, 1.11; C9, 5.39 (Ratios: 1: 13: 10: 34). Serial dilutions (in
triplicate) of the mAb (1–0 µg/ml) were made into HBS and
added to the wells at different stages of MAC formation to
determine the inhibition. Test and control mAb were added
either prior to addition of C7 (human or rat), or prior to addition
of C8/C9 and incubated for 30 min at 37°C. In some assay rat-
EDTA serum was used as source of rat C8 and C9 to develop lysis
of C5b-7 (human or rat C7) coated cells. Plates were centrifuged
at 2000 rpm for 3 min at 4°C, supernatants removed to a flat-
welled microtiter plate, absorbances measured spectrophometrically
(A405nm) and % lysis calculated.
To reduce the need for large volumes of fresh mouse serum,
add-back hemolytic assays were used for testing of lytic activity
in mice treated with the mAb. NHS depleted of C7 (C7D) or C5
(C5D) was used as source of the rest of the complement proteins;
mouse serum was added (1:2 v:v; mouse serum:C7D/C5D) to
restore the relevant component. The serum mix was diluted to
10% in HBS then plated in a dilution series (50 µl/well; 10–0%) in
HBS in a round bottommicrowell plate; 50 µl 2% ShEA and 50 µl
HBS were added (final concentrations of serummix in wells: 3.3–
0%), incubated for 30 min at 37°C. Plates were centrifuged,
supernatants removed to a flat-welled microtiter plate and
absorbance measured spectrophometrically (A405nm). % lysis
was calculated.
Characterization of Novel mAbs by ELISA
and WB
Direct ELISA was used to test whether the new mAb bound C7
from different species. Sandwich ELISA were used to confirm C7
binders, to eliminate issues around denaturation by protein
binding on plastic, and to test whether the mAbs competed for
the same binding epitope. Standard curves were generated using
in-house human or animal (rat, mouse, monkey) C7 proteins,
immunoaffinity purified as previously described (15). In the
direct ELISA, Maxisorp (Nunc, Loughborough, UK) 96-well
plates were coated with C7 (0.5 µg/ml in bicarbonate buffer,
pH 9.6) at 4°C overnight; wells were blocked (1 h) at 37°C with
2% bovine serum albumin (BSA) in phosphate-buffered saline
(PBS), washed in PBS containing 0.05% Tween 20 (PBS-T).
Dilutions of purified mAb, 1000–0 ng/ml (stock concentrations
of all proteins used established using the BCA assay) in 0.2%
BSA-PBS, were added in triplicate to wells coated with each of
the antigens and incubated for 1 h at 37°C. Wells were washed
with PBS-T then incubated (1 h, 37°C) with secondary antibody
(donkey anti-mouse-horseradish peroxidase (HRP); Jackson
ImmunoResearch, Ely, UK) for 1 h at 37°C. In the sandwich
ELISA, Maxisorp plates were coated with mAb (2 µg/ml in
bicarbonate buffer, pH 96) at 4°C overnight; wells wereDecember 2020 | Volume 11 | Article 612402
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Standard curves were generated using in-house purified C7
protein serially diluted in 0.2% BSA-PBS, added in triplicate
and incubated for 1 h at 37°C. Wells were washed with PBS-T
then incubated (1 h, 37°C) with the paired HRP-labeled mAb
(1 in 1000 dilution in PBS-T; Pierce, #31489). After washing, plates
were developed using O-phenylenediamine dihydrochloride
(OPD, Sigma FAST™; Sigma-Aldrich) and absorbance (492
nm) was measured. GraphPad Prism was used for data analysis.
To confirm specificity for C7 and the species reactivity, C7
protein (in house; 0.5 µg) or human or animal (mouse, rat,
monkey) sera diluted 1:100 in PBS were placed in separate wells
and resolved on 4–20% sodium dodecyl sulphate–polyacrylamide
gel (SDS-PAGE) electrophoresis gels (#4561093; Biorad, Hemel
Hempstead, UK) under reducing (R) and non-reducing (NR)
conditions, then electrophoretically transferred onto 0.45 µm
nitrocellulose membrane (GE Healthcare, Amersham, UK).
After transfer, non-specific sites on the membrane were blocked
with 5% BSA in PBS-T. After washing in PBS-T, membrane strips
were incubated overnight at 4°C with individual test mAb (each at
1 µg/ml in 5% BSA PBS-T) or polyclonal (goat) anti-human C7
(2 µg/ml, CompTech, Tyler, TX; A224). After washing, bound test
mAb were detected by incubation with donkey anti-mouse IgG-
HRP (#715-035-150, Jackson ImmunoResearch) and polyclonal
anti-C7 with rabbit anti-goat IgG HRP conjugate (#305-035-045;
Jackson ImmunoResearch) at 1: 10000 in 5% BSA PBS-T. Blots
were washed, developed with enhanced chemiluminescence (GE
Healthcare) and visualized by autoradiography.
To characterize mAb binding to soluble terminal complement
complexes (TCC), biotinylated mAbs (Pierce, #21327) were
individually added to human or rat serum (100 µg/ml in 3 ml
serum) and the mix activated via both classical and alternative
pathways by incubation with Zymosan A (7 mg/ml; #21327,
Pierce) and aggregated human IgG (1 mg/ml; in house) for 32 h
at 37°C in a shaking water bath. The reaction was stopped by
centrifugation at 2500 rpm for 15 min at 4°C and the supernatant
(activated serum) collected. For analysis by WB, supernatant was
mixed with 0.25 ml Avidin-coated beads (prepared by coupling
avidin to HiTrap N-hydroxysuccinimide-activated beads; #17-
0716-01, GE Healthcare, Little Chalfont, UK). The mixture was
incubated for 1 hat RT while mixing gently, the beads washed
five times in PBS by centrifugation (1000 rpm for 1 min) and the
bound mAb-complex eluted by incubation (10 min at 100°C) in
reducing or non-reducing SDS-PAGE running buffer.
Supernatants were subjected to SDS-PAGE and WB as above.
Blots were blocked with 5% BSA, washed, cut into strips and
individual strips incubated with goat anti-C5, -C6, -C7, -C8 or
-C9 antibodies (at 2 µg/ml, Comptech, Tyler, TX; A220, 223, 224,
225, 226) for 1 h, washed then incubated with horseradish
peroxidase HRP-conjugated anti-goat immunoglobulin (1: 10
000 dilutions, #305-035-045; Jackson ImmunoResearch) for 1 h
at RT with constant mixing. After washing, blots were developed
as described above. For analysis by ELISA, supernatant was
added to 96-well plates coated with Avidin (10 µg/ml),
incubated 1 h at 37°C and blocked with 2% BSA (1 h at 37°C);
after washing, terminal pathway components in the pull-downFrontiers in Immunology | www.frontiersin.org 4samples were detected with Goat anti-C5, C6, C7, C8 or C9
antibodies as above at 2 µg/ml diluted in 0.2% BSA PBS-T then
developed with rabbit anti-Goat-HRP, #305-035-045; Jackson
ImmunoResearch). Controls for each antibody comprised
biotinylated mAb alone or incubated with C7. The assay was
developed as described above.
Binding of the mAbs to pre-formed TCC was tested in ELISA;
serum activated as above in the absence of mAbs (1 in 50 dilution
in 0.2% BSA-PBS-T) was transferred to plates coated with aE11
anti-C9 neo-specific antibody (5 µg/ml, Hycult Biotech,
# HM2167), incubated 1 h at 37°C and blocked with 2% BSA
(1 h at 37°C); after washing, the new biotinylated mAb or as
positive control, an in house mAb known to bind aE11-captured
TCC (E2 anti-C8; 1 in 1000 dilution in 0.2% BSA-PBS-T) were
added and incubated for 1 h at 37°C, after washing, Streptavidin-
HRP (1 in 5000 dilution in 0.2% BSA-PBS-T, Fisher Scientific,
# 21130) was added, plates incubated 1 h at 37°C and the assay
developed as described above.SPR Analysis to Determine Test mAbs
Binding Affinity to Human C7
The mAbs binding analyses were carried out on a Biacore T200
instrument (GE Healthcare); for mAb of isotype IgG, an
antibody capture kit (GE Healthcare, # BR-1008-38) was used
to immobilize the mAb on a CM5 sensor chip (GE Healthcare,
#29-1496-03) as recommended by the manufacturer. mAb
isotype IgM was immobilized on a Protein L Series S sensor
chip (GE Healthcare #29-2051-38). mAb were flowed to saturate
the surface, then C7, human, rat or mouse, diluted in EP-HBS
(10 mM HEPES, pH 7.4, 150 mM NaCl, 0.005% surfactant P20)
in the range 0 to 68 nM, flowed over the immobilized mAb. For
kinetic analysis the flow rate was maintained at 30 µl/min, and
data were collected at 25°C. Data from a reference cell were
subtracted to control for bulk refractive index changes. The
Rmax was kept low and the flow rate high to eliminate mass
transfer. All reagents used were of high purity and polished by
size exclusion chromatography immediately before use to ensure
removal of any aggregates. Data were evaluated using Biacore
Evaluation Software (GE Healthcare).
In Vivo Testing of mAbs
To test in vivo mAb that blocked mouse complement in
hemolysis assays, wild type (WT) mice (C57BL/6J, bred in
house) were administered mAb by IP injection (1 mg in PBS,
40 mg/kg dose); controls included the blocking anti-mouse C5
mAb BB5.1 at the same dose. Blood was collected before mAb
administration and at intervals up to 48 h after for measurement
of hemolytic activity.
To test mAb that blocked human complement in hemolysis
assays, C7 deficient mice (homozygous C57BL/6NJ-C7em1(IMPC)
J/Mmjax, bred in house, n= 10) were injected intraperitoneally
(IP) with human C7 (500 µg), then split into test and control
groups (5 in each). One hour later, test group animals were
injected subcutaneously (SC) with blocking mAb (1 mg in PBS,
40 mg/kg dose), while control group mice were injected with anDecember 2020 | Volume 11 | Article 612402
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animals just before the experiment, 1 h after C7 administration
(immediately before giving the mAb) and at intervals after mAb
injection up to 48 h for measurement of hemolytic activity.
To test mAb that blocked rat complement in hemolysis
assays, Lewis rats (100–150 g; Charles River Laboratories,
Edinburgh, UK) were injected IP with 10, 20 or 40 mg/kg dose
of mAb (2 per group); blood was collected from all the animals
just before the experiment, and at intervals post-injection over a
time course of 7 days for measurement of hemolytic activity.
Testing mAb in an Experimental
Autoimmune Myasthenia Gravis (EAMG)
Rat Model
A rat complement-blocking mAb was tested in the rat EAMG
model. Lewis rats (100–150 g) were injected IP with anti-
Acetylcholine receptor (AChR) mAb35 at 1 mg/kg in PBS as
described previously (16–18). mAb35 binds the main
immunogenic region of AChR, activating complement and
damaging the neuromuscular junction endplates, causing
severe damage to motor function. Animals were assessed
hourly post-disease initiation as described previously. Clinical
symptoms were assigned based on a standardized scale 0 to 5: 0,
no disease; 1, reduced grip strength in front legs (can grip cage lid
but cannot lift) and floppy tail; 2, loss of grip in front legs; 3, loss
of grip and hind limb weakness and wasting; 4, loss of grip and
hind limb paralysis; 5, moribund. mAb35-injected rats were split
into two groups (n= 5 each), the test group received blocking
mAb at 10 mg/kg SC (determined in the dosing experiment) at
time zero, the control group received an irrelevant isotype
control antibody (D1.3) at the same times, routes and doses.
Blood was taken at intervals for hemolysis assays; all animals
were sacrificed at 48 h post-induction.
Soleus muscles were harvested and frozen in OCT mounting
medium for sectioning as described previously (16–18). Sections
were fixed in ice-cold acetone for 15 min at −80°C and then
blocked for 30 min in 10% horse serum/2% BSA. After washing
in PBS, sections were stained overnight at 4°C with primary
antibodies, C3/30 anti-C3b/iC3b mAb (in house) at 10 µg/ml,
and rabbit anti-rat C9/MAC polyclonal IgG (in house) at 50 µg/
ml, both in the block buffer. Anti-C3b/iC3b sections were washed
and incubated for 15 min at RT with amplifier antibody goat
anti-mouse (VectaFluor DyLight 488, # DK-2488; Vector Labs,
Peterborough, UK). After washing, secondary antibody, horse
anti-goat IgG–Alexa Fluor 488 (DyLight 488, # DK2488) for
C3b/iC3b or goat anti-rabbit-FITC (#45002; Oxford Biomedical
Research, Rochester Hills, MI, USA) for anti-C9/MAC were
added as appropriate, together with a-bungarotoxin-TRITC
(BtX) (labels AChR; Boitum, # 00012) at 0.5% and Hoechst
stain 1: 10 000 dilution (# 62249; ThermoFisher), then incubated
40 min at RT in the dark. Sections were washed in PBS and
mounted in VectorShield Vibrance (#H-1700-2; Vector Labs)
before analysis using an Apotome fluorescence microscope
(Zeiss Apotome Axio Observer microscope, Carl Zeiss
Microscopy, Cambridge, UK). Ten fields were captured from
comparable regions of muscle in each sample at the sameFrontiers in Immunology | www.frontiersin.org 5exposure and magnification (×20) and the number of BuTx-
reactive endplates in each section was measured using density
slicing in an image analysis system (ImageJ, University of
Wisconsin-Maddison, Maddison, WI, USA). For co-localization
of complement activation products, sections were additionally
imaged on a Zeiss confocal microscope (Zeiss LSM800 confocal
laser scanning microscope).
Statistical Analysis
All statistical analyses were performed using GraphPad Prism
software (v. 5.0, San Diego, California). Statistical significance
between two groups was obtained using the unpaired t-test and
for multiple groups using one-way ANOVA after testing for
normality. For all analyses, p<0.05 was considered significant.
Error bars in all figures represent mean ± standard error of
triplicates (unless otherwise stated. The SPR analysis was
performed in an automated manner using T200 Biacore
Evaluation Software version 2 (GE Healthcare).RESULTS
The Novel Blocking mAb Work Across
Species and Block Hemolysis by Binding
C7 and/or the C5b-7 Complex
In total, 15 fusions were performed; ~15,000 hybridoma clones
were generated and screened, 7 confirmed to be inhibitory, and
five of these, 2H2 (IgG2b, k), 3B11 (IgM, k), 17E7 (IgG2a, k),
59E7 (IgG2b, k), and 73D1 (IgG2a, k), chosen for full
characterization based upon the capacity of clone supernatants
to cause inhibition of CP hemolysis of ShEA by NHS, NRS or
NMS. All selected mAbs except mAb 17E7 were generated in C7
KO mice; 17E7 was produced in a WT mouse. All mAbs except
3B11 were purified using protein G chromatography, mAb 3B11,
an IgM mAb, was purified using ammonium sulphate
precipitation. The purified mAbs were tested in hemolysis
assays with different species sera (Figures 1A–D). Anti-C5
blocking mAbs were used as positive controls; commercial
mAbs eculizumab and crovalimab for NHS, BB5.1 for NMS
and in house mAb 7D4 for NRS (18, 19). As expected from the
selection process, each of the selected mAbs efficiently inhibited
CP hemolysis in one or more species sera; In NHS, mAbs 17E7,
59E7, 3B11 and 73D1 all inhibited in that order of efficiency; 2H2
inhibited weakly (Figure 1A). In NMkS 59E7, 73D1, and 17E7
inhibited in that order of efficiency; no inhibition was observed
with 2H2 (Figure 1D). In NRS, 2H2 was an exceptionally strong
inhibitor, at least ten-fold better than other mAbs in the assay;
73D1 and 3B11 also inhibited NRS in that order of efficiency, but
17E7, 59E7, and the commercial anti-human C5 mAb had no
inhibitory activity in NRS (Figure 1B). In NMS, mAbs 73D1,
2H2, and 3B11 inhibited in that order of efficiency, but 17E7,
59E7, and the C5-blocking controls 7D4 and eculizumab had no
inhibitory activity in NMS (Figure 1C). The 73D1 inhibition
profile closely matched that of BB5.1, the blocking anti-C5 mAb
used as positive control in this assay; crovalimab also inhibited
NMS as previously reported (Figure 1C) (19). None of the newDecember 2020 | Volume 11 | Article 612402
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species inhibitory activities of the mAbs are summarized in
Table 1; the calculated 50% complement inhibitory doses and
hemolytic units (HU) of all mAbs in the different sera are shown.
Serum excess assays (25% serum;10-fold serum dose compared
to titration assays above) were used to test mAb 17E7 and 2H2 inFrontiers in Immunology | www.frontiersin.org 6conditions that better reflect those prevailing in whole blood
(Figures 1E, F), confirming that these mAbs are efficient
complement inhibitors in human and rat serum respectively.
To identify the precise mechanism of complement inhibition
by the novel mAbs, reactive lysis assays were used. GPE were first





FIGURE 1 | Functional assays of C7-blocking mAbs. (A–D) Anti-C7 mAb were tested for blocking activity in classical pathway (CP) hemolysis (CH50) assays across
species. Sera tested were human (A), rat (B), mouse (C) and cynomolgus monkey (Cyno) (D). Anti-C5 mAb crovalimab (Crov), eculizumab (Ecul), BB5.1 and 7D4
were used as comparators. Test and control mAb were titrated in range 0–100 µg/ml. (E) Serum excess assay using NHS or NRS concentration 10-fold that used in
the standard CP assay; solid lines are NHS, dashed lines are NRS. (F) human C6D and C7D were reconstituted with purified human C6 or C7 (dashed lines)
respectively and the capacity of mAb 2H2 to inhibit hemolysis tested. (G, H) Reactive lysis assays using guinea pig erythrocytes (GpE) as target; for mAb 17E7,
59E7, and 73D1, purified human complement proteins (C5b6, C7, C8 and C9) were used; for mAb 2H2 and 73D1 human C5b6 and rat C7 were used with normal
rat serum (NRS) as the source of rodent C8 and C9. The mAb were either added to GpE-C5b6 before or after C7 addition (G); solid and dotted line respectively.
mAb 2H2 was added to washed GPE- C5b-7(rat) prior to addition of NRS as source of C8 and C9 (H). All experiments were repeated three times with the same
results. The error bars are standard errors of triplicates.December 2020 | Volume 11 | Article 612402
Zelek and Morgan Cross-Species C7 Blocking Monoclonal Antibodiesvarious doses (0–1 µg/ml) added either before or after C7
addition, followed by C8, C9. All mAb except 2H2 were tested
with purified human proteins; for mAb 2H2, purified rat C7 and
EDTA-NRS as a source of rat C8 and C9 were used with human
C5b6. All the 22 tested mAbs showed strong inhibition when
added to GPE-C5b6 before C7 was added. When added after C7,
mAb 17E7, 59E7, and 73D1 all showed no inhibition of lysis
(Figure 1G). To further test the mode of inhibition of mAb 17E7
the mAb was either pre-incubated with C7 prior to addition to
GPE-C5b6 or added simultaneously with C7; inhibition of lysis
was essentially the same with or without the pre-incubation
step, suggesting that the mAb efficiently captures fluid-phase C7
to prevent formation of an active C5b-7 complex (data
not shown).
In contrast to the other mAb, the rat-selective mAb 2H2
caused a dose-dependent inhibition of lysis even when added to
pre-formed GPE-C5b-7, implying that this mAb had a distinct
mechanism of inhibition compared to the other mAb, working at
least in part by binding and blocking C5b-7 thus preventing C8
binding to the complex (Figure 1H). When tested in a reactive
lysis system using human C5b6, rat C7 and either human C8/C9
or NRS as a source of C8/C9, mAb 22H2 effectively blocked lysis
when incubated with pre-formed GPE-C5b-7(rat) and washed to
remove free mAb prior to addition of either human C8/C9 or
NRS, confirming the findings with human C7 above and
demonstrating that the species source of C8/C9 (human or rat)
did not impact the effect (Figure 1H). To further test species
specificity of mAb 2H2, rat C6D was reconstituted with human
C6 and rat C7D with human C7; in each case, 2H2 strongly
inhibited lysis in a dose-dependent manner, implying that this
mAb is selective for the C5b-7 complex (Figure 1F).Frontiers in Immunology | www.frontiersin.org 7The Novel mAbs Bind Native C7 and C7 in
the TCC Complex in Serum
The direct ELISA showed that all the selected new mAbs
recognized human C7; mAb 2H2, 3B11, and 73D1 also bound
rat C7, while mAb 73D1 bound mouse C7. mAb 17E7 and 73D1
were strongly cross-reactive with non-human primate
(cynomolgus) C7 (Figure 2A; Table 1). In competitive
sandwich ELISA, C7 was not detected with any mAb pair
suggesting that they compete for similar epitopes on C7; all
mAb worked in sandwich ELISA with goat anti-C7 as either
capture or detect (Figure 2B). mAb 2H2 when used as capture
and goat anti-C7 as detection also detected rat C7, demonstrating
that the mAb recognizes C7 from both species.
WB was used to confirm binding of mAbs to C7. The human-
specific mAb 59E7 and 17E7 detected C7 in human and
cynomolgus monkey serum under NR conditions (Figure 3A);
these mAb did not detect C7 in other species sera, confirming the
ELISA results above. The species cross-reactive mAb 73D1 and
3B11 specifically detected C7 in human, rat, mouse and
cynomolgus monkey sera under NR conditions (Figures 3B,
C). None of the mAb detected C7 in sera under R conditions
(negative data not shown). mAb 2H2 did not bind the human C7
standard, detected by all other mAbs; it did weakly detect C7 in
all sera tested under NR conditions but also identified multiple
high molecular weight bands in the MW range 160 to 260 kDa
that may represent C7 aggregates or terminal pathway complexes
in serum (Figure 3D). To further explore the nature of these,
pull-down assay from rat or human serum activated with
zymosan and aggregated IgG in the presence of biotinylated
2H2 was performed; remarkably, mAb 2H2 pulled down all the
terminal pathway proteins from both rat and human serum,
indicating that it bound the fluid phase TCC when present
during activation (Figures 3F, G). Pull-downs from activated
human serum performed as above but using biotinylated mAb
17E7, 59E7, and 73D1, showed that each of the antibodies also
pulled down all the terminal pathway proteins C5b–C9,
demonstrating capacity of each of these mAbs to bind C7 in
the forming TCC (Figures 3H–J).
Binding of the novel mAbs to TCC when present during serum
activation was confirmed in sandwich ELISA on pull-downs from
rat or human serum using the mAbs as above. All terminal
pathway proteins: C5b, C6, C7, C8, and C9 were detected in the
pull-downs; the strongest signals were observed with C5b, C6, and
C7 proteins (Figure 2D). All the new mAb also bound the pre-
formed TCC (captured on aE11 anti-C9 neospecific antibody) in
activated human serum, giving signals at similar levels to the
positive control E2 anti-C8 antibody, confirming that they bind C7
in the pre-formed TCC (Figure 2C). The aE11 mAb also captured
TCC from activated rat serum and this was detected using the rat
C7-reactive mAb 2H2 (Figure 2C). Taken together, the data show
that each of the mAb recognize C7 in the TCC both when present
in the fluid phase during TCC generation, and when added post-
activation to the preformed complex.
SPR analysis on immobilized antibody with human or rat C7
flowed over confirmed binding of the novel mAbs to human and/
or rat C7. The measured kinetics/affinity are summarized inTABLE 1 | Summary of novel anti-C7 and control anti-C5 blocking mAb tested.






17E7 IgG2a,k Human 55.1 181.6 Strong
Monkey 1.9 530.3 Strong
59E7 IgG2b,k Human 47.7 209.7 Strong
Monkey 10.1 98.7 Strong
3B11 IgM,k Human 19.9 501.9 Strong
Rat 11.9 839.5 Moderate
2H2 IgG2b,k Human 1.0 9977.0 Weak
Rat 264.8 33.9 Strong
Mouse 2.7 3715.4 Weak
73D1 IgG2a,k Human 17.2 581.8 Strong
Monkey 3.8 261.1 Strong
Rat 19.8 505.5 Strong
Mouse 13.9 720.3 Strong
mAb anti-C5 controls
7D4 IgG2b,k Human 69.3 144.2 Strong
Rat 9.5 1054.4 Moderate
BB5.1 IgG1,k Mouse 16.3 613.6 Strong
Crovalimab IgG1,k Human 49.9 212.3 Strong
Monkey 8.6 115.5 Strong
Mouse 1.4 1862.1 Weak
Eculizumab IgG2/
4,k
Human 47.1 181.6 StrongInhibitory dose: <750, strong; 750–1500, moderate; >1500, weak.December 2020 | Volume 11 | Article 612402
Zelek and Morgan Cross-Species C7 Blocking Monoclonal AntibodiesTable 2. The mAb 17E7 and 59E7 showed very strong binding to
human C7 in SPR analyses (KD = 1.02 × 10−9, 9.31 × 10−10
respectively) (Figure 3K) with negligible off rates, suggesting that
17E7 and 59E7 are promising candidates for human
therapeutics. Binding of mAb 3B11 and 73D1 to human or rat
C7 was relatively weak (human KD = 2.30 × 10−7 and 5.55 ×
10−8; rat KD =1.93 × 10−7 and 8.17 × 10−8) (Supplementary
Figure 1); however, both these mAb showed a slow off rate for rat
C7 offering promise for use in vivo. Additionally, mAb 73D1
showed strong binding to mouse C7 (KD = 2.31 × 10−9) with a
very slow off rate, promising for testing in mouse models.
Analysis by SPR of immobilized 2H2 showed no measurable
binding to native human, rat or mouse C7 in multiple analyses
(negative data not shown).
The Novel mAbs Are Efficient Complement
Inhibitors In Vivo
The capacity of mAbs to inhibit complement in vivo was tested in
mice and rats. To test the capacity of the anti-mouse C7 mAb
73D1 to inhibit complement in vivo, WTmice were administeredFrontiers in Immunology | www.frontiersin.org 873D1 (or BB5.1 anti-mouse C5 as positive control) IP and
complement activity in serum was tested at intervals over a
time course of 48 h. Complement was inhibited by both mAb
over the full course of the experiment up to end-point at 48 h
(Figure 4A). To test the capacity of the anti-human C7 mAb
17E7 to inhibit C7 in vivo, mAb was administered to C7-deficient
mice reconstituted with human C7. Human C7 effectively
restored hemolytic activity in the mice, and administration of
mAb 17E7 efficiently inhibited hemolytic activity in the mice
(>70% inhibited at 3 h post-administration) compared to
irrelevant antibody, demonstrating that the mAb blocked
human C7 in vivo (Figure 4B). The rat-selective mAb 2H2
was tested for complement inhibition in rats to determine dose
requirement and antibody half-life. Rats were injected with mAb
2H2 at 10, 20, and 40 mg/kg and blood collected at intervals for
testing hemolytic activity. Even at the lowest dose, the mAb was
an effective inhibitor, blocking complement activity for >48 h,
and at the highest dose blocked complement for at least a week




FIGURE 2 | Direct and sandwich ELISA to determine mAb binding to human, monkey, rat and mouse C7. (A) Direct ELISA: plates were coated with human,
monkey (cyno), rat or mouse C7; mAbs were tested in a dilution series (0–10 µg/ml). The graph shows representative binding with the 10 µg/ml capture.
(B) Sandwich ELISA: the new mAbs were paired as capture and detect with human C7 used in a dilution series (0–5 µg/ml). The graph shows representative binding
with 5 µg/ml C7. As a positive control, polyclonal anti-C7 (goat anti-C7) was used as capture with each of the mAb as detect; rat C7 captured on goat anti-C7 (goat
anti-C7; rat C7) was also tested with the mAb as detect. (C) Sandwich ELISA to detect pre-formed TCC in activated NHS; TCC in activated NHS (and NRS for 2H2)
was captured on aE11 anti-C9 and the novel mAbs and the positive control E2 anti-C8 mAb used to detect the TCC complex captured. (D) TCC complexes
generated in NHS (or NRS for 2H2) in the presence of each of the new mAb (biotinylated) were captured on avidin-coated plates, then polyclonal antibodies against
each of the terminal complement proteins used to test the presence of the respective components in the complex. The error bars are standard errors of triplicates.
All experiments were repeated three times with the same results.December 2020 | Volume 11 | Article 612402
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FIGURE 3 | Western blotting to detect C7 binding in serum and in TCC. (A) The human-specific mAbs 59E7 and 17E7 were used to probe WB of NHS (Hu) and
Cynomolgus monkey (Mk) serum under non-reducing (NR) conditions. Secondary only control was included (2°). (B–E) The cross-species reactive mAbs 73D1 (B),
3B11 (C) and 2H2 (D) and as control the polyclonal goat anti-C7 (E) were used to probe WB of NHS (Hu), monkey (Mk), mouse (Mo) and rat sera; purified human
C7 was used as standard. All sera were run in duplicate. Polyclon3B11 (C), 2H2 (D), and positive control goat anti-C7 (E). Results are representative of three
independent experiments. M; protein molecular weight marker. (F–J) The novel mAbs were used to pull down complexes from activated serum; these were then run
on WB under non-reduced and reduced conditions and probed with polyclonal antibodies against each of the terminal complement proteins. mAb 2H2 was used in
rat (F) and human (G) serum; the other mAbs in human serum only (H–J). The blots were cut into strips prior to probing to detect the individual terminal pathway
proteins. Molecular weights used were: NR: C5, 190 kDa; C6, 105 kDa; C7, 95 kDa, C8ag; 70 kDa; C9, 65 kDa. R: C6, 110 kDa; C7, 95 kDa; C5b, 75 kDa; C9, 70
kDa; C8a/b, 65 kDa; C8g, 22 kDa. Results are representative of at least three analyses. M; protein molecular weight marker, 2°; secondary antibody. (K) The novel
mAbs 17E7, 59E7 and 73D1 were separately immobilized on mouse IgG capture sensor chips (GE Healthcare, # BR-1008-38) and mAb 3B11 (IgM) on protein
L Series S sensor chip (GE Healthcare #29-2051-38) at approximately 60 RU. Human, rat or mouse C7 was flowed in HEPES-buffered saline (HBS) in a dilution
range of 66 to 8 nM and interactions with the immobilized mAbs were analyzed. Sensorgrams were collected and KDs were calculated using the Langmuir 1: 1
binding model with RI values set to zero. Representative sensorgrams for 17E7 and 59E7 binding of human C7 are shown with raw data in colored lines and fitted
data in dotted line (average of 3); all binding data and analyses are included in Table 2. The sensorgrams of clones 3B11 and 73D1 are included in Supplementary.
The SPR analysis was performed in an automated manner using T200 Biacore Evaluation Software version 2 (GE Healthcare).
Zelek and Morgan Cross-Species C7 Blocking Monoclonal AntibodiesThe Rat-Selective mAb 2H2 Prevents Clinical
Disease and Pathology in a Myasthenia Model
EAMG was passively induced in rats; at the time of disease
induction, the rat-selective mAb 2H2 or isotype control (10 mg/kg;
5 per group) was administered SC. As expected, all isotype
control treated rats began to lose weight and show symptoms,
comprising limp tails, piloerection, hind limb weakness and
reduced grip strength within 24 h; all had a clinical score of 4
by endpoint (Figures 4D, E). (15–17) In contrast, animals given
mAb 2H2 subcutaneously at the time of disease induction
continued to gain weight over the time course of the
experiment and did not develop detectable weakness or other
clinical manifestations for the duration of the experiment
(Figures 4D, E). Animals were sacrificed by a Schedule 1
method when weight loss was equal to or exceeded 20% of
original bodyweight, when clinical score reached 4, or at the 48 h
endpoint. CP hemolytic activity in serum was absent in the 2H2-
treated group throughout the experiment (Figure 4F). As
expected, serum from the untreated control animals retained
full hemolytic activity across the time course. Soleus muscles
were harvested at sacrifice, stained with a-Bungarotoxin-TRITC
and receptor numbers quantified. The number of endplates in
isotype control treated animals was significantly lower than in
mAb 2H2-treated animals (~three-fold less; P < 0.0001, Figure
4G); endplate numbers in the 2H2-treated rat were comparable
to numbers in naïve animals (data not shown). Endplates in
muscles from the EAMG group were frequently fragmented,
whereas most endplates in the 2H2-treated group were intact
and linear, as in naïve animals. There was no significant
difference in C3 fragment staining between the 2H2-treated
and isotype control-treated animals (P = 0.9792, Figure 4H);
however, the intensity of C9/MAC staining was reduced moreFrontiers in Immunology | www.frontiersin.org 10than threefold in the 2H2-treated group (P = 0.0011, Figure 4I).
Confocal analysis demonstrated co-localization of C3b/iC3b and
C9/MAC deposition at the endplate in isotype control animals at
48 h (Figure 4J); in 2H2-treated animals, C3b/iC3b was
deposited to a similar degree at endplates but C9/MAC deposition
was weak or absent (Figure 4K).DISCUSSION
The pathological role of complement in diverse diseases has been
apparent for more than 50 years (20–23). Despite this long
history, to date the use of anti-complement drugs has been
restricted to a handful of rare diseases, including hemolytic
disorders such as PNH and renal diseases, notably aHUS,
where they have had a transformational impact (1–3).
Eculizumab was first approved for treatment of PNH thirteen
years ago, but only very recently have new anti-complement
drugs reached the market and disease targets remain restricted to
rare conditions (1). Recent reports provide irrefutable evidence
that complement drives pathology in more common diseases
including multiple sclerosis, NMOSD and AMD (24–26);
however, because of the cost and route of administration, use
of eculizumab in these diseases is not feasible; more affordable
and effective drugs are needed. Complement proteins are
abundant in plasma (~5% of total plasma protein), and the
majority are acute phase reactants, increasing synthesis and
plasma concentration in response to infection. This is a
particular issue for C5 blockade; breakthrough hemolysis is a
recognized complication in patients on eculizumab, likely
because even a tiny amount of free C5 (<0.1%) is sufficient to
restore hemolytic activity (27–29). These issues led us to consider
other targets in the terminal pathway; we focused on C7 for four
reasons: i). Plasma concentrations of C7 are lower than those of
C5 (~2-fold lower molar concentration); ii). Unlike the other
terminal pathway components, C7 is not synthesized by
hepatocytes and is not an acute phase reactant, hence levels of
C7 are stable in acute phase conditions (30); iii). Blocking C7 is
likely to be less of an infection hazard compared to C5 blockade
because C5a-mediated neutrophil recruitment is unimpaired -
indeed, the majority of patients with C7 deficiency are healthy,
although at increased risk of Neisserial infections (31); iv).TABLE 2 | SPR analysis of the binding of C7 to the immobilized mAb.
Antibody KD (M) Ka (1/Ms) Kd (1/s)
17E7 Human; 1.02 × 10−9 6.83 × 104 6.94 × 10−5
59E7 Human; 9.31 × 10−10 1.45 × 106 1.4 × 10−3
3B11 (protein L captured) Human; 2.30 × 10−7





73D1 Human; 5.55 × 10−8
Rat; 8.17 × 10−8






2.36 × 10−4December 2020 | Volume 11 | Article 612402
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FIGURE 4 | Testing anti-C7 mAbs in vivo. (A) mAb 73D1 or BB5.1 anti-mouse C5 as positive control was administered IP at a dose of 1 mg/kg to female wildtype
mice (n=5 per group); blood was sampled at intervals serum obtained and added to human C7D or C5D serum respectively prior to measuring CP hemolytic activity
measured. Controls included C7D and C5D human sera at the same dose, NMS to demonstrate the requirement for human depleted sera and 1% Tween-20 and
HBS to set 100% and 0% lysis in the assay. Significance of differences between groups was determined by one-way ANOVA; significant differences and p values are
shown in the figure. Error bars are standard errors of triplicates. (B) C7-deficient mice (10 females) were reconstituted with human C7 (500µg; IP), then split into test
and control groups (5 in each). After 1 h, test and control animals were injected subcutaneously (SC) with 17E7 mAb or irrelevant isotype control mAb (1 mg)
respectively. Blood was collected prior to administration of C7, immediately prior to administration of mAb and 3 h after mAb administration. Hemolytic activity was
measured as above. Significance of differences between groups was determined using an unpaired t test; significant differences and p values are shown in the figure.
Error bars are standard errors of triplicates. (C) Female Lewis rats were divided into three groups (n = 2 each) and injected intraperitoneally with mAb 2H2 at doses
of 10, 20, and 40 mg/kg; blood was collected from all the animals just before mAb administration, 2 h after mAb 2H2 administration, and then every 12 h over 1
week. Sera prepared and hemolytic activity tested in standard CP assays. Significance of differences between groups was determined using an unpaired t test;
significant differences and p values are shown in the figure. Error bars are standard errors of triplicates. (D–F) EAMG was induced in rats (5 per group) and either
mAb 2H2 or isotype control mAb(10mg/kg) administered at induction. Weight loss (D) and clinical score (E) were measured at intervals; mice were bled at 0, 2, 24,
and 48 h, serum harvested and hemolytic activity measured (F). All animals were killed at 48 h. Results are means of five in each group and vertical bars represent
SD. Significance of differences between groups was determined using an unpaired t test except panel E where paired t test was used; significant differences and p
values are shown in the figures. (G–K). Soleus muscles were harvested at time of sacrifice (48 h) and snap frozen in OCT. Sections (10 µm) were stained for AChR
with TRITC-conjugated a-BuTX; AChR-positive endplates were counted in 10 fields from each animal using ImageJ software. (G). Sections were stained for C3b/
iC3b (H) and C9/MAC (I) and staining quantified as above. Tissue sections from isotype control (J) or 2H2 (K) treated animals were double-stained for AChR
together with anti-C3b/iC3b (top panel) or C9/MAC (bottom panel) and imaged on a Zeiss confocal microscope. The scale bar shown is 10 µm; all images were
captured at identical magnification. Statistical significance was obtained by unpaired t-test and P < 0.05 was considered significant; significant differences and p
values, mean and SD are shown in the figures.
Zelek and Morgan Cross-Species C7 Blocking Monoclonal AntibodiesC7 has been neglected as a therapeutic target, in contrast to C5
where numerous Pharma companies are developing blocking
mAb or other drugs.
To identify clones secreting blocking anti-C7 mAbs early in
clone screening we used a high-throughput hemolysis assay;
notably, C7-blocking mAb were rare events, only 7 inhibitory
clones identified from 15,000 screened clones over 15 separate
fusions. Although we did not test for non-blocking anti-C7 mAbs
in all fusions, this was done in early fusions and C7-binding
activity was detected in ~5% of clones screened. This contrasts
markedly with our experience with C5 where ~10% of the anti-C5
mAb generated were strong function blockers (17). The mAb
described here bound C7 in ELISA (Figure 2A) and inhibited lysis
of ShEA in CP assays (Figure 1) with mAb 17E7 and 59E7 being
the most efficient for human serum; these mAb gave similar
inhibition profiles to the currently available therapeutic anti-C5
mAb eculizumab and crovalimab. The mAb were generated in C7-
deficient mice and several showed strong cross-species activity.
The mAb 2H2 was most effective for rat serum and 73D1 for
mouse serum; mAb 3B11 efficiently inhibited both human and rat
serum (Table 1). Inhibition by 17E7 and 2H2 was confirmed in a
modified CP assay using near-physiological serum concentrations.
The in vitro inhibition data was confirmed in vivo for the mouse
C7-blocking mAb 73D1, and for the human C7-specific mAb
17E7, the latter tested in C7-deficient mice administered human
C7. Mouse serum inhibition by 73D1 was equivalent to the anti-
C5 blocker BB5.1 (Figure 4A), widely used in animal models (19)
and catalyzing the enthusiasm for anti-C5 therapeutics; the
efficient inhibition of mouse complement by mAb 73D1 make it
a valuable tool for animal studies targeting MAC specifically
without interfering with C5a generation.
Both of the human C7-specific mAbs, 17E7 and 59E7, showed
strong and stable binding to human C7 in SPR (KD = 1.02 ×
10−9, 9.31 × 10−10, respectively; Table 2). Strong binding of mAb
73D1 to mouse C7 was also confirmed by SPR analysis (KD =
2.31 × 10−9, Table 2). Epitope specificity was tested in ELISA;Frontiers in Immunology | www.frontiersin.org 12surprisingly, all of the antibodies reactive with a given species C7
gave no signal when used as a pair in sandwich ELISA, showing
that they bound the same or overlapping epitopes on C7 (Figure
2B). All the mAb worked as detect or capture in sandwich ELISA
in conjunction with a polyclonal anti-C7, demonstrating that all
bound C7 in this context. These observations suggest that there is
a dominant epitope or surface of the C7 molecule that is critical
for function and the target for all selected mAb. We plan
structural studies to identify this epitope as we recently
described for the anti-C5 mAb BB5.1 (19).
The mAb 2H2 stood out from the other mAb generated; this
rat-selective mAb was a highly efficient complement inhibitor in
vitro inhibiting at a dose at least 10-fold lower than the other in-
house blocking mAb; at this dose, C7 is in ~10-fold molar excess
compared to the mAb. Although 2H2 recognized C7 protein
immobilized on plastic in direct ELISA, when tested in SPR
immobilized on the chip surface, this mAb did not capture either
human or rat C7 flowed over the surface. In vivo, this mAb
completely blocked serum lytic activity at a quarter of the dose
routinely used in rodent models (10 mg/kg versus 40 mg/kg body
weight) for other terminal pathway inhibitory mAb, including
BB5.1, the in-house anti-rat C5 4G2, and the 73D1 anti-C7 mAb
(18, 19). When administered at the standard dose, 2H2 effectively
blocked complement for at least seven days in rats, compared to
48 h for the other mAb at the same dose. Rats treated with the
lowest dose of mAb 2H2 showed complete loss of hemolytic
activity and were protected from disease compared to controls in
the EAMG model; treated rats did not lose weight or develop
paralysis, endplates were protected from damage and MAC
deposition at endplates was markedly reduced (Figures 4D–K).
Taken together, the above data demonstrating that mAb 2H2
binds denatured but not native C7 and blocks hemolytic activity
in vitro and in vivo at much lower concentrations than other
blocking mAb and when C7 is in molar excess, suggested that
2H2 has a different mechanism of action to the other blocking
mAb. We reasoned that it might inhibit by binding the transientDecember 2020 | Volume 11 | Article 612402
Zelek and Morgan Cross-Species C7 Blocking Monoclonal AntibodiesC5b-7 complex. To test this, we used reactive lysis assays; all the
blocking mAb, including 2H2, inhibited lysis when added to
C5b6-bearing cells prior to addition of C7, indicating that they
either prevented binding of C7 to C5b6 or its unfolding to reveal
C8-binding sites. When the blocking mAb were added to
preformed C5b-7 cells, only 2H2 inhibited suggesting that it
additionally bound to C5b-7 and blocked C8 binding (Figures
1G, H). It was not possible to test directly the impact of 2H2 on
the fluid-phase C5b-7 complex in these assays because of the
transience of C5b-7 membrane-binding activity; instead, we
explored binding of 2H2 and the other blocking mAb to
forming and formed TCC in the fluid phase. Pull-downs from
rat serum activated in the presence of mAb 2H2 included all
terminal pathway proteins C5b–C9, demonstrating that the mAb
captures intermediates in the fluid phase while permitting
binding of later components to generate a mAb-TCC complex
(Figures 3F, G). The anti-human C7 mAb 17E7, 59E7, and
73D1, when incubated in human serum during activation as
above, each pulled down all the TCC components demonstrating
that they too bound C7 in the complex and did not interfere with
fluid-phase TCC generation (Figures 3H–J). Binding of the
novel mAbs to pre-formed TCC was confirmed by sandwich
ELISA capturing the complex on the aE11 anti-C9 neo-specific
antibody (Figures 2C, D).
In some respects, the mechanism of action of mAb 2H2
resembles that of the naturally occurring MAC inhibitor
clusterin; this fluid phase regulator binds C5b-7, preventing
membrane attachment and insertion of the complex, but
allows recruitment of C8 and C9 to form the TCC (32–34).
Clusterin is a weak inhibitor of hemolysis that “buffers”
bystander effects. The Streptococcal inhibitor of complement
(SIC) protein similarly binds fluid-phase intermediates
(predominantly C5b-7) and blocks the capacity of the complex
to associate with membranes (35, 36). In contrast to 2H2, neither
clusterin nor SIC caused inhibition in reactive lysis when C5b-7
was already on the target surface, confirming that they only
interfere with membrane binding of nascent C5b-7. The capacity
of 2H2 to bind and inhibit membrane-bound C5b-7 complexes
suggests a dual impact on C5b-9 assembly; these properties make
mAb 2H2 a powerful MAC inhibitor, a “super-clusterin”
working with much greater efficiency to inhibit MAC assembly
and resultant lysis.
In summary, we have demonstrated that, with regard to blocking
hemolytic activity in vivo and in vitro, targeting MAC downstream
of C5 is at least as effective as targeting C5. We describe anti-C7
mAbs that are powerful blockers of human, primate, rat and mouse
C7, several working across species.We describe one mAb, 2H2, that
shows selectivity for the C5b-7 complex and inhibits at greatly
reduced dose compared to component-specific mAbs; although this
mAb is predominantly active in rat, it is proof of principle that
complex-specific mAb can be generated. These have potentially
great advantages over current anti-complement drugs in terms of
dose, frequency of administration and infection risk; they have the
potential to open up new therapeutic fields for anti-complement
drugs with significantly lower cost of treatment and more suited to
treatment of common, chronic diseases. Current efforts are focusedFrontiers in Immunology | www.frontiersin.org 13on the development of 2H2-like mAb that bind and block the
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SUPPLEMENTARY FIGURE 1 | Binding sensorgrams of the novel mAbs to C7
protein. mAb 3B11 (IgM) was immobilized on a protein L Series S sensor chip (GE
Healthcare #29-2051-38) and mAb 73D1 (IgG2a, k) immobilized on a mouse IgG
capture sensor chip (GE Healthcare, # BR-1008-38) at approximately 60 RU.
Human, rat or mouse C7 was flowed in HEPES-buffered saline (HBS) in a dilution
range of 66 to 4 nM (3B11) or 66 to 8 nM (73D1) and interactions with the
immobilized mAbs were analyzed. Sensorgrams were collected and KDs calculated
using the Langmuir 1: 1 binding model with RI values set to zero. Sensorgrams are
shown with raw data in colored lines and fitted data in dotted lines (average of 3); all
binding data and analyses are included in Table 2. The SPR analysis was
performed in an automated manner using T200 Biacore Evaluation Software
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